CALT News and Press, Calliditas Therapeutics AB From 04/27/21

Calliditas Therapeutics AB: Change in financial calendar PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first qu...

Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...

Notice of annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM , April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm , are summoned to t...

EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy PR Newswire STOCKHOLM , April 23, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its lead p...

Calliditas strengthens its US Commercial and Medical Affairs Organization PR Newswire STOCKHOLM , March 8, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced the appointment of three industry veterans: Warren Brooks , PhD,...

Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice PR Newswire STOCKHOLM , March 4, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today ann...

Calliditas Therapeutics: Year-End Report, 2020 Positive Topline Results from Pivotal Phase 3 NefIgArd Trial PR Newswire STOCKHOLM , Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020 , we announced positive topline readout of Part A of our Phase 3 pivotal...

First Patient Dosed in NefIgArd Open Label Extension Study PR Newswire STOCKHOLM , Feb. 4, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient has been dosed in the global open-label extension (OLE) of th...

Calliditas Therapeutics AB (CALT) has announced that the company has terminated the previously announced proposed global offering due to deterioration in market conditions."Calliditas is well capitalized with a cash runway into Q3 of 2022 and we believe there are financing options which ...

Calliditas announces termination of the proposed global offering PR Newswire STOCKHOLM , Jan. 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; Nasdaq - CALT) today announced that despite significant interest, it wil...